viral shedding Clinical Research Trials

Catalysing the Containment of COVID-19

COVID-19 due to SARS-CoV-2 infection is a rapidly escalating global pandemic for which there is no proven effective treatment. COVID-19 is multi-dimensional disease caused by viral cytopathic effects and host-mediated immunopathology. Therapeutic approaches should logically be based on interventions that have direct anti-viral effects and favourably modulate the host immune …

ebola virus disease

nitazoxanide

organ failure

antihypertensive drugs

interferon

42 views
25 Jan, 2021
1 location

Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients

The purpose of this study is to assess the duration of the viral shedding in hematology and oncology patients after a respiratory tract viral infection. This duration has not been much studied

1 views
24 Jan, 2021
1 location

Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

This study will evaluate the efficacy of oral Foipan (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients

0 views
26 Jan, 2021
1 location

Effects of Surgical Mask Use on Peak Torque Total Work and Interset Fatigability During Isokinetic Strength Testing

are recommended at all levels for source control as a simple barrier to help prevent respiratory droplet transmission. It is important to remember that increased viral shedding occurs during elevated

0 views
27 Jan, 2021
1 location

NNITS-Nitazoxanide for Norovirus in Transplant Patients Study

prolonged therapy with nitazoxanide, lack of interactions with common post-transplant medications, putative antiviral activity and prolonged duration of viral shedding we are assessing 56 doses of therapy

82 views
27 Jan, 2021
13 locations

Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

oropharyngeal viral shedding.

coronavirus infection

anosmia

fever

oropharyngeal

SARS

0 views
27 Jan, 2021
29 locations

The Containing Coronavirus Disease 19 (COVID-19) Trial

type 1 interferon (IFN) can potentially eliminate the spread of SARS-CoV-2. IFN could reduce the period of viral shedding by ~1 week. Since pre-symptomatic shedding of virus can start up to 5 days

0 views
26 Jan, 2021
1 location

Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy

It still unclear how SARS-CoV-2 affects pregnant women and their offspring, as well as which factors may influence obstetrical disease and outcomes, including the timing of maternal viral exposure by gestational age, the effects of parity, age, host immune responses, coexisting medical and obstetrical conditions and the effects of treatment …

anosmia

myalgia

headache

hydroxychloroquine

fever

251 views
27 Jan, 2021
4 locations

Control of COVID-19 Outbreaks in Long Term Care

To address the need to intervene to prevent the spread of COVID-19 in long-term care homes, we propose a randomized clinical trial of chemoprophylaxis in long-term care homes experiencing COVID-19 outbreaks. LTCH units experiencing an outbreak of COVID-19 will be randomized to chemoprophylaxis with favipiravir or placebo in a 1:1 …

covid-19

favipiravir

post-exposure prophylaxis

0 views
26 Jan, 2021
1 location

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

This study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate …

anticoagulation therapy

international normalized ratio

neutrophil count

platelet count

treatment regimen

24 views
26 Jan, 2021
53 locations

Filter By

Found 33 clinical trials